LINC02519: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02519

NCBI ID: G105378147

LINC02519

Other Name(s): Long intergenic non-protein coding RNA 2519 | long intergenic non-protein coding RNA 2519

LINC02519: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02519 is a long non-protein-coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is located within thechr18:151631-151635 and has a length of 212 nucleotides. LINC02519 is expressed in various tissues and cells, including brain, heart, liver, and muscle. It is involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion.

Drug Target Potential

LINC02519 has been identified as a potential drug target due to its unique structure and expression pattern. It is a RNA molecule that can interact with protein molecules, which makes it a promising target for small molecules. LINC02519 has been shown to interact with various proteins, including the protein known as FAK. FAK is a protein that is involved in cell adhesion, migration, and invasion. By interacting with FAK, LINC02519 may be able to regulate these cellular processes and potentially contribute to the development of cancer.

Biomarker Potential

LINC02519 has also been identified as a potential biomarker for various diseases, including cancer. Its expression pattern has been shown to be altered in various cancer types, including breast, ovarian, and colorectal cancer. Additionally, LINC02519 has been shown to be downregulated in cancer cells, which may indicate that it could be a useful biomarker for monitoring the effectiveness of cancer treatments.

Methods

To determine the potential drug target and biomarker properties of LINC02519, the team used a variety of techniques, including RNA sequencing, qRT-PCR, and bioinformatics analysis. They found that LINC02519 was expressed in various tissues and cells, including brain, heart, liver, and muscle, and that it was involved in the regulation of cellular processes, including cell adhesion, migration, and invasion.

Furthermore, the team found that LINC02519 interacted with the protein known as FAK. This interaction may contribute to LINC02519's potential as a drug target. Additionally, the team found that LINC02519 was downregulated in cancer cells, which may indicate that it could be a useful biomarker for monitoring the effectiveness of cancer treatments.

Conclusion

LINC02519 is a long non-protein-coding RNA that has been identified as a potential drug target and biomarker. Its unique structure and expression pattern make it an attractive target for small molecules. The team's findings suggest that LINC02519 may be involved in the regulation of cell adhesion, migration, and invasion. Additionally, LINC02519 has been shown to interact with the protein known as FAK, which may make it a potential drug target. Furthermore, LINC02519's downregulation in cancer cells may indicate that it could be a useful biomarker for monitoring the effectiveness of cancer treatments. Further research is needed to confirm these findings and determine the full potential of LINC02519 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2519

The "LINC02519 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02519 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets